Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year?

Company Overview - ADC Therapeutics SA (ADCT) is a notable stock within the Medical group, which comprises 929 companies and holds the 10 position in the Zacks Sector Rank [2] - The Zacks Rank system focuses on earnings estimates and revisions to identify stocks with improving earnings outlooks, with ADC Therapeutics currently rated 2 (Buy) [3] Performance Analysis - Over the past three months, the Zacks Consensus Estimate for ADCT's full-year earnings has increased by 24.9%, indicating improved analyst sentiment and a more positive earnings outlook [4] - Year-to-date, ADC Therapeutics has returned 6.5%, outperforming the Medical sector's average return of 6% [4] - In comparison to its specific industry, Medical - Biomedical and Genetics, which has gained about 21.1% this year, ADCT is slightly underperforming [6] Industry Context - The Medical - Biomedical and Genetics industry includes 450 stocks and is currently ranked 88 in the Zacks Industry Rank [6] - Another stock, Assertio (ASRT), has significantly outperformed the sector with a year-to-date return of 29.3% and is rated 1 (Strong Buy) [5] - The Medical - Drugs industry, where Assertio belongs, has 141 stocks and has seen a modest increase of 2.9% this year [7]